Overview

Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

Status:
Active, not recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

This is a randomized phase 3 trial aiming to compare the efficacy of docetaxel and hormone therapy as second line treatment in patients with mCRPC progressing after therapy with abiraterone or enzalutamide.

Phase:

Phase 3

Details

Lead Sponsor:

National Cancer Institute, Naples

Treatments:

Abiraterone Acetate
Docetaxel
Hormones
Prednisone